Inventor
VISSER MICHAEL SCOTT
US17 patents
⚠️ This page may combine multiple inventors who share the name “VISSER MICHAEL SCOTT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
14 patentsUS10647701B2May 12, 2020
3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
NOVARTIS AG13 citations93
US10640489B2May 5, 2020
3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
NOVARTIS AG13 citations93
US10414755B2Sep 17, 2019
3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
NOVARTIS AG18 citations93
US9845309B2Dec 19, 2017
Protein kinase C inhibitors and methods of their use
NOVARTIS AG6 citations83
US11192877B2Dec 7, 2021
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
NOVARTIS AG6 citations81
US11505541B2Nov 22, 2022
Protein kinase C inhibitors and methods of their use
NOVARTIS AG1 citations72
US11059804B2Jul 13, 2021
Protein kinase C inhibitors and methods of their use
NOVARTIS AG3 citations72
US10508101B2Dec 17, 2019
Protein kinase C inhibitors and methods of their use
NOVARTIS AG3 citations72
US11053218B2Jul 6, 2021
3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
NOVARTIS AG4 citations71
US11413284B2Aug 16, 2022
Protein kinase C inhibitors for treatment of uveal melanoma
NOVARTIS AG2 citations69
US12570625B2Mar 10, 2026
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
NOVARTIS AG0 citations59
US12208097B2Jan 28, 2025
Protein kinase C inhibitors for treatment of uveal melanoma
NOVARTIS AG0 citations59
US9126979B2Sep 8, 2015
Compounds for inhibiting the interaction of BCL2 with binding partners
NOVARTIS AG0 citations41
US9126980B2Sep 8, 2015
Compounds for inhibiting the interaction of BCL2 with binding partners
NOVARTIS AG0 citations40